# Zosano Pharma Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zosano-pharma

- Industry: Biotechnology
- Headquarters: Fremont, US
- Website: www.zosanopharma.com
- Total disclosed funding: $115M
- Latest round: Series C (Aug 18, 2010)
- Investors on record: 4

## About

Zosano Pharma Corporation is a biopharmaceutical company focused on developing innovative transdermal delivery systems for therapeutic agents, particularly in pain management and other medical conditions.Founded in 2006, Zosano Pharma Corporation is based in Fremont, US, and specializes in advanced transdermal delivery systems. The company went public in January 2015, raising USD 50 mn through an IPO, before being acquired by Emergex Vaccines Holding Limited in October 2022 for USD 1 mn. The firm has completed 12 deals to date, with the latest deal being an ADD-ON Trade Sale. Michael Magnano, the founder, has experience in the biopharmaceutical sector, contributing to the company's strategic direction alongside CEO Gail Schulze, Joseph Hagan, Kleanthis Xanthopoulos, and Steven Lo.Zosano Pharma Corporation develops transdermal delivery systems aimed at improving patient outcomes by providing controlled release of medications. Their primary focus is on pain management therapies, utilizing their proprietary technology to enhance the bioavailability and patient compliance of drugs. The company markets its products globally, targeting both established and emerging markets to address diverse medical needs.In the most recent fiscal year of 2021, Zosano Pharma Corporation reported a revenue of USD 785,000 and an EBITDA of USD -29,781,000. This revenue is generated through its innovative product offerings, which cater to various market segments in the healthcare sector.Following the acquisition in October 2022, Zosano Pharma Corporation aims to leverage the recent funding to enhance its product pipeline, focusing on upcoming therapies in pain management. The company plans to expand into new markets in Europe and Asia-Pacific by 2025, utilizing its advanced transdermal delivery technology to meet local healthcare needs. The recent funding of USD 1 mn from Emergex Vaccines Holding Limited will support these initiatives, including further development and potential launches of new therapeutic products.

## Funding rounds

- Series C, Aug 18, 2010, $2.4M — New Enterprise Associates, HBM Partners, ProQuest Investments, Phase4 Partners
- Series B, Jul 6, 2009, $30M — New Enterprise Associates, HBM Partners, ProQuest Investments, Phase4 Partners
- Series A, Nov 15, 2007, $45M — New Enterprise Associates, HBM Partners, ProQuest Investments, Phase4 Partners
- Series B, Oct 10, 2006, $38M — New Enterprise Associates, HBM Partners, Phase4 Partners

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series B, Series A, Series C
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series B, Series A, Series C
- Phase4 Partners (https://capitalatlas.ai/funds/phase4-partners) — Series B, Series A, Series C
- ProQuest Investments (https://capitalatlas.ai/funds/proquest-investments) — Series A, Series B, Series C